Use of rituximab in idiopathic retroperitoneal fibrosis
Abstract Background Retroperitoneal fibrosis (RPF) is characterized by the proliferation of fibrous tissue in the retroperitoneum. The majority of RPF cases are due to idiopathic or IgG4-related disease. Recent studies on IgG4-related disease have shown rituximab to be an effective treatment. The cu...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-08-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41927-020-00140-9 |